Melbourne start-up Hexima applies to test GM cotton
02 February, 2004 by Graeme O'NeillMelbourne plant biotechnology company Hexima has applied to the Office of the Gene Technology Regulator to conduct a small field trial of transgenic cotton lines containing its novel protease-inhibitor genes.
MCRI deal with Quintiles to triple clinical trial activity
29 January, 2004 by Melissa TrudingerThe Murdoch Children's Research Institute (MCRI) in Melbourne has entered into an alliance with international clinical trials organisation Quintiles to bring international paediatric clinical trials to the institute's clinical trials group.
BioDiem lists on ASX after successful IPO
28 January, 2004 by Graeme O'NeillMelbourne pharmaceutical company BioDiem has listed on the Australian Stock Exchange (ASX:BDM), cashed up with AUD$12 million to fund its research and development program.
Gradipore touts technology's commercial potential
27 January, 2004 by Melissa TrudingerSydney-based bioseparations specialist Gradipore (ASX:GDP) claims to have successfully completed proof-of-principle studies demonstrating scale-up of its Gradiflow technology to commercial levels.
Research, biobusiness honoured in Australia Day awards
27 January, 2004 by Iain ScottLast week, ResMed's California-based chairman and CEO Dr Peter Farrell was in his usual stirring form at a Melbourne speech, referring to Australia as "Botswana" and the nation's flag as a "dog's breakfast". But perhaps he was just getting it all out of his system one last time -- on Monday, Farrell was named a Member of the Order of Australia (AM), one of the top gongs in the annual Australia Day honours
Starpharma has option to ditch PDF status
23 January, 2004 by Melissa TrudingerThe board of Melbourne nanotechnology company Starpharma (ASX:SPL) has been given the discretion to give up the company's pooled development fund (PDF) status if it becomes necessary.
Victory in sight on war against Johne's disease
23 January, 2004 by Graeme O'NeillIt's a Gollum of a pathogen: sneaky, tough, persistent, and able to remain hidden from its host's immune system as it goes about its nefarious business.
Gradipore names neighbour Minomic as distributor
22 January, 2004 by Melissa TrudingerSydney-based Gradipore (ASX:GDP) has entered into a non-exclusive distribution agreement with Sydney-based proteomics specialists Minomic to distribute its Gradiflow BF400 bioseparation instrument nationally.
New trial for Progen melanoma therapy
21 January, 2004 by Graeme O'NeillQueensland oncology drug-discovery company Progen Industries has begun a new Phase I/II clinical study of its lead anti-cancer compound PI-88 in patients with malignant melanoma.
CSL, Chiron move to Phase II hep C vaccine trial
20 January, 2004 by Graeme O'NeillThe hopes of hundreds of thousands of people around the world chronically infected with hepatitis C virus could be riding on an Australian clinical trial of a new, potentially life-saving vaccine being jointly developed by US-based Chiron Corporation and Melbourne pharmaceutical company CSL (ASX:CSL).
Fewer farmer objections to GM crops
20 January, 2004 by Graeme O'NeillA national survey of Australian farmers' views on genetically modified (GM) crops has identified a marked shift in sentiment during the past 12 months, with fewer farmers now opposed.
Biotron wins Start grant for virus blocker trials
19 January, 2004 by Graeme O'NeillCanberra biotechnology company Biotron (ASX:BIT) has been offered a $1.66 million Commonwealth R&D Start grant to begin clinical development and testing of novel compounds designed to disrupt replication of the AIDS virus.
UNSW spin-off Biosignal to list in reverse takeover
19 January, 2004 by Melissa TrudingerBiosignal, a spin-off from the University of NSW, is to list on the ASX in late March through a reverse takeover of CTI Communications (ASX:CTC), a telecommunications services company.
Xeno virus no problem: researcher
16 January, 2004 by Graeme O'NeillA new US finding, that transplanted human cells can form pig-human hybrid cells in foetal pigs, does not present a new hazard for transplants of humanised pig organs or cells into humans, according to a leading Melbourne xenotransplantation researcher.
pSivida to trade on German exchanges
15 January, 2004 by Melissa TrudingerPerth-based nanotech company pSivida (ASX:PSD) will soon commence trading on the German stock exchanges in Berlin, Munich and Stuttgart after meeting all listing requirements, the company has announced.
